This evolving landscape is tightening its grip on an industry already struggling to keep pace with patient demand, and small molecule drug developers are feeling the pinch most acutely.

The three platform deals are long-term bets, but broaden Genentech’s drug discovery capabilities, particularly in small-molecule R&D. The Convelo deal focuses on the development of novel drug ...

Some 36% of small businesses have seen their premiums increase since 2023, according to J.D. Power's 2024 U.S. Small Commercial Insurance Study, which surveyed customer satisfaction among business ...

IPC Indice de Precios Y Cotizaciones 56,720.12 338.12 0.60% ...

Given that PHGDH is such an important enzyme, there are past studies on its possible inhibitors. One small molecule, known as NCT-503, stood out to the researchers because it is not quite effective at ...

Still, most portfolio holdings are small- or micro-cap companies. These tend to be lower quality and more volatile than their larger counterparts. The Russell 2000 Index does not incorporate any ...

As an undergrad at Harvard, Danna Freedman went to a professor’s office hours for her general chemistry class and came across an elegant paper model that depicted the fullerene molecule.

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

State Street Small/ Mid Cap Eq Idx Port earns an Above Average Process Pillar rating. Morningstar's algorithmically assigned Passive Process ratings are first formulated by comparing the ...

You can also ask for custom pay-per-view content and porn to be delivered directly to your inbox from this hot small boobs OnlyFans star, she is happy to consider your requests. Just as you would ...

In recent years, structure-based drug design has facilitated the development of lysine-targeting covalent inhibitors. The CoDEL technology is rapidly emerging as a key platform for covalent drug ...

The Company expects to initiate the 13-week Phase IIa study in the U.S. at the beginning of the third quarter of 2025. ASC30 was discovered and developed in-house at Ascletis as a first and only ...